Track Adaptimmune Therapeutics plc — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Adaptimmune Therapeutics plc ADAP Open Adaptimmune Therapeutics plc in new tab

0.0485 USD
EPS
-0.66
P/B
-0.20
ROE
-1341.10
Beta
2.49
Target Price
0.68 USD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 11, 2026
EPS-0.66
Book Value-0.27
Price to Book-0.20
Debt/Equity93.13
% Insiders0.631%
Growth
Revenue Growth-0.89%
Estimates
Forward P/E-0.11
Forward EPS-0.38
Target Mean Price0.68

DCF Valuation

Tweak assumptions to recompute fair value for Adaptimmune Therapeutics plc (ADAP)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Adaptimmune Therapeutics plc Logo Adaptimmune Therapeutics plc Analysis (ADAP)

United Kingdom Health Care Official Website Stock

Is Adaptimmune Therapeutics plc a good investment? Adaptimmune Therapeutics plc (ADAP) is currently trading at 0.0485 USD. Market analysts have a consensus price target of 0.68 USD. This suggests a potential upside from current levels.

Earnings Schedule: Adaptimmune Therapeutics plc is expected to release its next earnings report on May 11, 2026. The market consensus estimate for Forward EPS is -0.38.

Investor FAQ

Does Adaptimmune Therapeutics plc pay a dividend?

No, it does not currently pay a dividend.

What asset class is Adaptimmune Therapeutics plc?

Adaptimmune Therapeutics plc is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 11, 2026. The company currently has a trailing EPS of -0.66.

Company Profile

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Exchange Ticker
NMS (United States) ADAP
FRA (Germany) 473A.F
STU (Germany) 473A.SG

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion